Investment
Features
FeesSafety
Academy
More
Pluang+

Compare United States Copper Index Fund (CPER) vs Heron Therapeutics Inc (HRTX) Price & Performance

United States Copper Index FundTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

United States Copper Index Fund vs Heron Therapeutics Inc — how do they compare? United States Copper Index Fund trades at $40.1 (market cap $708.28M), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: United States Copper Index Fund is far larger — about 10.4× Heron Therapeutics Inc's market cap, and United States Copper Index Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Heron Therapeutics Inc for 35 Days on average.

CPERHRTX
Market Cap
$708.28M$68.01M
Volume
339,0461,891,941
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$41.43$1.49
52-Week Low
$30.27$0.27
Typical Hold Time
48 Days35 Days
Enterprise Value
—$174.75M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

United States Copper Index Fund

CPER is trading at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish momentum in moving averages but neutral oscillators, with key support at $39 and resistance at $40. Recent news highlights strong copper demand driven by AI infrastructure needs, though copper prices have shown volatility with recent declines.

The outlook for CPER is mixed, with positive copper demand fundamentals balanced by near-term price volatility. Investment opportunities center on exposure to copper's role in AI and electrification trends, while risks include commodity price swings and potential supply chain disruptions. Wall Street sentiment appears cautiously optimistic given copper's strategic importance.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.

While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CPER
1% Buy99% Sell
Avg holding period · 48 Days
HRTX
8% Buy92% Sell
Avg holding period · 35 Days

About United States Copper Index Fund

CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.

Read more on CPER →

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →